Prurigo nodularis (PN) is one of the most challenging and underdiagnosed skin conditions in dermatology. Patients suffer from intensely itchy nodules that form a vicious itch-scratch cycle, and for decades, truly effective treatments remained elusive. That is now changing.
What Is Prurigo Nodularis?
PN is a chronic inflammatory skin condition characterized by firm, dome-shaped nodules, typically 1 to 3 centimeters in size, that develop in response to repeated scratching or picking. The nodules are intensely pruritic (itchy), causing severe sleep disruption, anxiety, and depression.
PN can affect any part of the body but typically spares the mid-back (the “butterfly sign”, an area the patient cannot reach to scratch).
The Itch-Scratch Cycle
PN exists at the intersection of neurology and dermatology:
- Itch triggers scratching
- Scratching traumatizes the skin, triggering nerve growth
- Increased nerve density amplifies itch signaling
- Heightened itch drives more scratching
- Nodules form from repetitive mechanical trauma
Breaking this cycle requires addressing both the inflammatory and neurological components simultaneously.
Who Is Affected?
PN is estimated to affect over 300,000 Americans. It is more prevalent in older adults, those with atopic dermatitis, and people with conditions associated with systemic itch (kidney disease, liver disease, thyroid disorders).
The New Era of PN Treatment
In 2022, dupilumab (Dupixent) became the first FDA-approved treatment specifically for prurigo nodularis. Clinical trials showed dramatic reductions in itch and nodule count. Additional biologics targeting IL-31 (nemolizumab) are in late-stage development.
If you have been diagnosed with PN and are not achieving adequate relief, clinical trial participation may provide access to investigational treatments. Contact NuLine to learn about current studies.